Daré Bioscience Cash Flow Statement Analysis
Values in millions USD
| Breakdown | TTM | FY 2025 | FY 2024 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Period ending | Sep 2026 | Dec 2025 | Mar 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Mar 2019 | Dec 2017 |
| Operating Activities | ||||||||||||
| Net Income | -10.58 | -13.40 | -4.05 | -4.05 | -30.16 | -30.95 | -38.70 | -38.70 | -27.40 | -14.26 | -16.74 | -11.50 |
| Depreciation & Amortization | 2.17 | 2.15 | 0.04 | 0.04 | 0.04 | 0.02 | 0.03 | 0.03 | 0.04 | 0.01 | 0.00 | 0.00 |
| Stock Based Compensation | 1.55 | 1.50 | 2.20 | 2.20 | 2.53 | 2.16 | 1.60 | 1.60 | 0.74 | 0.46 | 0.14 | 0.02 |
| Change in Working Capital | -10.65 | -0.21 | 5.81 | 5.89 | -10.43 | 10.70 | 8.73 | 8.73 | 1.54 | 0.71 | 0.63 | 1.14 |
| Change in Accounts Receivable | -0.22 | -0.34 | 0.72 | 0.72 | 0.75 | -0.56 | -0.69 | -0.69 | 0.10 | -0.20 | 0.25 | 0.66 |
| Change in Accounts Payable | -1.04 | -0.26 | -1.93 | -1.93 | 1.36 | -0.08 | 1.08 | 1.08 | -0.06 | 0.61 | 0.15 | 0.75 |
| Change in Other Working Capital | -5.06 | 0.39 | 7.02 | 5.00 | -4.57 | 3.57 | 8.33 | -0.65 | 0.96 | 0.30 | 0.48 | 0.39 |
| Other Operating Activities | -0.67 | 0.08 | 1.39 | 0.79 | -0.84 | -0.02 | -0.42 | -0.42 | -0.16 | -0.23 | 5.69 | 7.81 |
| Net Cash from Operating Activities | -17.70 | -9.89 | 5.39 | 5.47 | -38.86 | -18.09 | -28.76 | -28.76 | -25.23 | -13.32 | -10.27 | -2.54 |
| Investing Activities | ||||||||||||
| Capital Expenditures | -0.49 | -0.39 | -0.57 | -0.57 | -0.63 | -0.06 | -0.01 | -0.01 | -0.02 | 0.00 | -0.01 | 0.00 |
| Acquisitions | - | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | - | 0.00 | 6.14 | -0.51 | 9.92 |
| Other Investing Activities | - | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | -0.51 | 9.92 |
| Net Cash from Investing Activities | -0.49 | -0.39 | -0.57 | -0.57 | -0.63 | -0.06 | -0.01 | -0.01 | -0.02 | 6.14 | -0.52 | 9.92 |
| Financing Activities | ||||||||||||
| Debt Repayment | -1.19 | -0.39 | -0.02 | -0.58 | -0.33 | 0.00 | 0.00 | - | 0.37 | 0.00 | 0.00 | 0.16 |
| Common Stock Issued | 7.16 | 20.93 | 0.45 | 0.45 | 9.35 | 1.34 | 75.31 | 75.85 | 24.76 | 5.15 | 10.11 | 0.00 |
| Other Financing Activities | - | -1.26 | 0.00 | -0.08 | 4.72 | 0.12 | 0.53 | - | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Cash from Financing Activities | 6.62 | 19.28 | 0.43 | 0.35 | 15.64 | 1.34 | 75.85 | 75.85 | 25.13 | 5.15 | 10.11 | 0.16 |
| Summary | ||||||||||||
| Effect of Forex Changes on Cash | 0.03 | 0.01 | -0.07 | -0.07 | -0.01 | -0.20 | -0.06 | -0.06 | 0.01 | -0.01 | -0.08 | -0.02 |
| Net Change in Cash | -11.54 | 9.01 | 5.19 | 5.19 | -23.86 | -17.00 | 47.00 | 47.00 | -0.11 | -2.03 | -0.75 | 7.52 |
| Cash at Beginning of Period | 23.08 | 16.00 | 10.81 | 10.81 | 34.67 | 51.67 | 4.67 | 4.67 | 4.78 | 6.81 | 7.56 | 0.04 |
| Cash at End of Period | 11.83 | 25.01 | 16.00 | 16.00 | 10.81 | 34.67 | 51.67 | 51.67 | 4.67 | 4.78 | 6.81 | 7.56 |
| Free Cash Flow | -18.19 | -10.27 | 4.82 | 4.90 | -39.49 | -18.15 | -28.78 | -28.78 | -25.25 | -13.32 | -10.28 | -2.54 |
Source: Company financial statements from annual and quarterly filings. Data as of Sep 30, 2026. Data sources and methodology
